Telix Pharmaceuticals Acquires Glioblastoma Program from Therapeia
Telix is pleased to announce a product development partnership with Therapeia GmbH & Co KG (“Therapeia”).
Wilex Signs Antibody License Agreement With Telix Pharmaceuticals Limited
Telix is delighted to have established this licensing agreement with Wilex for an important product with the potential to significantly impact cancer care.